Can Pregabalin Be Given to a 13-Year-Old?
Yes, pregabalin can be given to a 13-year-old, but ONLY for partial-onset seizures as adjunctive therapy—it is NOT approved for pain conditions (neuropathic pain, fibromyalgia) in pediatric patients under 18 years of age. 1
FDA-Approved Pediatric Indications
The FDA label explicitly states that pregabalin is approved for:
- Partial-onset seizures (adjunctive therapy): Ages 1 month and older 1
- NOT approved for: Neuropathic pain (diabetic, postherpetic, spinal cord injury) or fibromyalgia in patients under 18 years 1
Dosing for a 13-Year-Old with Seizures
For a 13-year-old with partial-onset seizures, dosing depends on body weight:
- If ≥30 kg: Start at 2.5 mg/kg/day, can increase to 10 mg/kg/day 1, 2
- If <30 kg: Requires 40% higher dose (3.5-14 mg/kg/day) to achieve equivalent drug exposure 1, 3
The 10 mg/kg/day dose demonstrated statistically significant efficacy in reducing seizure frequency (21% greater reduction vs placebo, p=0.0185) in pediatric patients aged 4-17 years 1, 2. The 2.5 mg/kg/day dose showed numerical but not statistically significant improvement 1.
Safety Profile in Adolescents
Most common adverse effects (≥5%) in pediatric seizure trials 1, 2:
- Somnolence (25.8% at 10 mg/kg/day)
- Weight gain (13.4%)
- Increased appetite (10.3%)
Critical safety warnings apply to all ages 1:
- Suicidal thoughts/behavior (1 in 500 risk with antiepileptic drugs)
- Serious breathing problems, especially with concurrent CNS depressants
- Dizziness and sleepiness affecting daily activities
- Allergic reactions (angioedema)
What About Pain Conditions in Adolescents?
Pregabalin is NOT FDA-approved for pain in pediatric patients. A 15-week trial in adolescents (ages 12-17) with fibromyalgia failed to show statistically significant benefit over placebo, despite numerical improvement 1. The safety profile was similar to adults, but efficacy was not established 1.
For neuropathic pain conditions (diabetic neuropathy, postherpetic neuralgia, spinal cord injury), there are no adequate studies in pediatric patients, and safety/effectiveness have not been established 1.
Clinical Decision Algorithm
For a 13-year-old patient:
Is the indication partial-onset seizures?
- YES → Pregabalin is appropriate as adjunctive therapy
- NO → Pregabalin is NOT FDA-approved; consider alternative agents
If seizures, what is the patient's weight?
- ≥30 kg → Use standard pediatric dosing (2.5-10 mg/kg/day)
- <30 kg → Increase dose by 40% (3.5-14 mg/kg/day)
Screen for contraindications:
- History of angioedema
- Concurrent opioids or CNS depressants (increased respiratory depression risk)
- History of substance abuse (pregabalin is Schedule V controlled substance)
- Psychiatric history (increased suicidal ideation risk)
If pain condition:
- Do NOT use pregabalin off-label in this age group
- Consider FDA-approved alternatives for pediatric pain management
Important Caveats
Juvenile animal toxicity data raise concerns 1: Rats exposed to pregabalin from early postnatal period through sexual maturity showed neurobehavioral abnormalities (learning/memory deficits, altered locomotor activity) and reproductive impairment at doses producing plasma exposures similar to human therapeutic doses. Some effects persisted after drug discontinuation, representing potential long-term consequences.
Renal dosing adjustments are mandatory: Pregabalin is renally eliminated, and dose reduction is required in renal impairment 4. This is particularly relevant in diabetic patients who may have concurrent nephropathy.
Gradual discontinuation is essential: Abrupt withdrawal can precipitate seizures and other serious problems 1. Taper slowly under medical supervision.